Toll-like receptors: a new target in rheumatoid arthritis?

References

• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med.344(12), 907–916 (2001).
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell85(3), 307–310 (1996).
   PubMed Web of Science ®Google Scholar
• Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N. Engl. J. Med.333(3), 142–146 (1995).
   PubMed Web of Science ®Google Scholar
• Furst DE. The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis. Clin. Exp. Rheumatol.17(1), 39–40 (1999).
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet344(8930), 1105–1110. (1994).
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol.19, 163–196 (2001).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med.130(6), 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum.48(1), 35–45 (2003).
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum.41(12), 2196–2204 (1998).
   PubMed Web of Science ®Google Scholar
• Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum.39(7), 1092–1101 (1996).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum.50(6), 1761–1769 (2004).
   PubMed Web of Science ®Google Scholar
• Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann. Rev. Immunol.7, 445–480 (1989).
   PubMed Web of Science ®Google Scholar
• Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM. Molecular therapeutic targets in rheumatoid arthritis. Expert Rev. Mol. Med.7(16), 1–20 (2005).
   PubMedGoogle Scholar
• Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med.349(20), 1907–1915 (2003).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum.52(8), 2263–2271 (2005).
   PubMed Web of Science ®Google Scholar
• Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther.7(Suppl. 2), S21–S25 (2005).
   Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345(15), 1098–1104. (2001).
   PubMed Web of Science ®Google Scholar
• Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum.39(5), 732–735 (1996).
   PubMed Web of Science ®Google Scholar
• Krause A, Kamradt T, Burmester GR. Potential infectious agents in the induction of arthritides. Curr. Opin. Rheumatol.8(3), 203–209 (1996).
   PubMedGoogle Scholar
• Silman AJ, MacGregor AJ, Thomson W et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol.32(10), 903–907 (1993).
   Google Scholar
• Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med.298(16), 869–871 (1978).
   PubMed Web of Science ®Google Scholar
• Corrigall VM, Panayi GS. Autoantigens and immune pathways in rheumatoid arthritis. Crit. Rev. Immunol.22(4), 281–293 (2002).
   PubMed Web of Science ®Google Scholar
• Vos K, Steenbakkers P, Miltenburg AM et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis.59(7), 544–548 (2000).
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature416(6881), 603–607 (2002).
   PubMed Web of Science ®Google Scholar
• Halfon MS, Keshishian H. The Toll pathway is required in the epidermis for muscle development in the Drosophila embryo. Dev. Biol.199(1), 164–174 (1998).
   PubMed Web of Science ®Google Scholar
• Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell86(6), 973–983 (1996).
   PubMed Web of Science ®Google Scholar
• Radstake TR, Roelofs MF, Jenniskens YM et al. Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. Arthritis Rheum.50(12), 3856–3865 (2004).
   PubMed Web of Science ®Google Scholar
• Seibl R, Birchler T, Loeliger S et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol.162(4), 1221–1227 (2003).
   PubMed Web of Science ®Google Scholar
• Iwahashi M, Yamamura M, Aita T et al. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum.50(5), 1457–1467 (2004).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. TLR signaling. Cell. Death Differ.13(5), 816–825 (2006).
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol.17(1), 1–14 (2005).
   PubMed Web of Science ®Google Scholar
• Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity7(6), 837–847 (1997).
   PubMed Web of Science ®Google Scholar
• Burns K, Martinon F, Esslinger C et al. MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem.273(20), 12203–12209 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang FX, Kirschning CJ, Mancinelli R et al. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem.274(12), 7611–7614 (1999).
   PubMed Web of Science ®Google Scholar
• Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science278(5343), 1612–1615 (1997).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell110(2), 191–202 (2002).
   PubMed Web of Science ®Google Scholar
• Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity28(4), 197–208 (1998).
   PubMed Web of Science ®Google Scholar
• Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity11(1), 115–122 (1999).
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature413(6851), 78–83 (2001).
   PubMed Web of Science ®Google Scholar
• Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol.2(9), 835–841 (2001).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sato S, Mori K et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol.169(12), 6668–6672 (2002).
   PubMed Web of Science ®Google Scholar
• Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol.4(2), 161–167 (2003).
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Rowe DC, Barnes BJ et al. LPS-TLR4 signaling to IRF-3/7 and NF-{kappa}B involves the Toll adapters TRAM and TRIF. J. Exp. Med.198(7), 1043–1055 (2003).
   PubMed Web of Science ®Google Scholar
• Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, Seya T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to Toll-like receptor 4 TICAM-1 that induces interferon-β. J. Biol. Chem.278(50), 49751–49762 (2003).
   PubMed Web of Science ®Google Scholar
• Hacker H, Redecke V, Blagoev B et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature439(7073), 204–207 (2006).
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol.4(7), 499–511 (2004).
   PubMed Web of Science ®Google Scholar
• Kawai T, Takeuchi O, Fujita T et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol.167(10), 5887–5894 (2001).
   PubMed Web of Science ®Google Scholar
• Takaoka A, Yanai H, Kondo S et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature434(7030), 243–249 (2005).
   PubMed Web of Science ®Google Scholar
• Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J. Biol. Chem.280(44), 36560–36566 (2005).
   PubMed Web of Science ®Google Scholar
• Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-κB activation. Science309(5742), 1854–1857 (2005).
   PubMed Web of Science ®Google Scholar
• Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol.76(3), 514–519 (2004).
   PubMed Web of Science ®Google Scholar
• Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev.204, 27–42 (2005).
   PubMed Web of Science ®Google Scholar
• Sacre SM, Drexler SK, Foxwell BM. Toll-like receptors and rheumatoid arthritis: is there a connection? In: Toll-like Receptors in Inflammation. O’Neill LAJ, Brint E (Eds), Birkhauser, Basel, Switzerland, 19–40 (2005).
   Google Scholar
• Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol.233(2), 90–96 (2005).
   PubMed Web of Science ®Google Scholar
• Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol. Ann.17(Pt 2), 229–259 (1982).
   Google Scholar
• Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell. Biol.16(6), 663–669 (2004).
   PubMed Web of Science ®Google Scholar
• Platt N, da Silva RP, Gordon S. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol.8(9), 365–372 (1998).
   PubMed Web of Science ®Google Scholar
• Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med.191(3), 423–434 (2000).
   PubMed Web of Science ®Google Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med.5(11), 1249–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Vollmer J, Tluk S, Schmitz C et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med.202(11), 1575–1585 (2005).
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Ahmad-Nejad P, da Costa C et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem.276(33), 31332–31339 (2001).
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem.277(17), 15107–15112 (2002).
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Braedel S, Hilf N et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J. Biol. Chem.277(23), 20847–20853 (2002).
   PubMed Web of Science ®Google Scholar
• Roelofs MF, Boelens WC, Joosten LA et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J. Immunol.176(11), 7021–7027 (2006).
   PubMed Web of Science ®Google Scholar
• Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins as activators of the innate immune system. Trends Immunol.23(3), 130–135 (2002).
   Google Scholar
• Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor α release by murine macrophages. J. Biol. Chem.278(1), 174–179 (2003).
   PubMed Web of Science ®Google Scholar
• Bausinger H, Lipsker D, Ziylan U et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur. J. Immunol.32(12), 3708–3713 (2002).
   PubMed Web of Science ®Google Scholar
• Reed RC, Berwin B, Baker JP, Nicchitta CV. GRP94/gp96 elicits ERK activation in murine macrophages. A role for endotoxin contamination in NF-κB activation and nitric oxide production. J. Biol. Chem.278(34), 31853–31860 (2003).
   PubMed Web of Science ®Google Scholar
• Liu B, Dai J, Zheng H, Stoilova D, Sun S, Li Z. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl Acad. Sci. USA100(26), 15824–15829 (2003).
   PubMed Web of Science ®Google Scholar
• Baker-LePain JC, Sarzotti M, Nicchitta CV. Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo.J. Immunol.172(7), 4195–4203 (2004).
   PubMed Web of Science ®Google Scholar
• Andersson U, Wang H, Palmblad K et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med.192(4), 565–570 (2000).
   PubMed Web of Science ®Google Scholar
• Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood101(7), 2652–2660 (2003).
   Google Scholar
• Park JS, Arcaroli J, Yum HK et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell Physiol.284(4), C870–C879 (2003).
   PubMed Web of Science ®Google Scholar
• Park JS, Svetkauskaite D, He Q et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem.279(9), 7370–7377 (2004).
   PubMed Web of Science ®Google Scholar
• Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol.290(3), C917–C924 (2006).
   PubMed Web of Science ®Google Scholar
• Yanagishita M, Hascall VC. Cell surface heparan sulfate proteoglycans. J. Biol. Chem.267(14), 9451–9454 (1992).
   PubMed Web of Science ®Google Scholar
• Kainulainen V, Wang H, Schick C, Bernfield M. Syndecans, heparan sulfate proteoglycans maintain the proteolytic balance of acute wound fluids. J. Biol. Chem.273(19), 11563–11569 (1998).
   PubMed Web of Science ®Google Scholar
• Lohmander LS, Dahlberg L, Ryd L, Heinegard D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum.32(11), 1434–1442 (1989).
   PubMed Web of Science ®Google Scholar
• Oragui EE, Nadel S, Kyd P, Levin M. Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria. Crit. Care Med.28(8), 3002–3008 (2000).
   PubMed Web of Science ®Google Scholar
• Weigel PH, Fuller GM, LeBoeuf RD. A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J. Theor. Biol.119(2), 219–234 (1986).
   PubMed Web of Science ®Google Scholar
• Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol.168(10), 5233–5239 (2002).
   PubMed Web of Science ®Google Scholar
• Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med.195(1), 99–111 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J. Biol. Chem.279(17), 17079–17084 (2004).
   PubMed Web of Science ®Google Scholar
• Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest.115(8), 2223–2233 (2005).
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J. Cell Biol.127(6 Pt 2), 2037–2048 (1994).
   PubMed Web of Science ®Google Scholar
• George J, Wang SS, Sevcsik AM et al. Transforming growth factor-β initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am. J. Pathol.156(1), 115–124 (2000).
   PubMed Web of Science ®Google Scholar
• Saito S, Yamaji N, Yasunaga K et al. The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism. J. Biol. Chem.274(43), 30756–30763 (1999).
   PubMed Web of Science ®Google Scholar
• Hino K, Shiozawa S, Kuroki Y et al. EDA-containing fibronectin is synthesized from rheumatoid synovial fibroblast-like cells. Arthritis Rheum.38(5), 678–683 (1995).
   PubMedGoogle Scholar
• Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem.276(13), 10229–10233 (2001).
   PubMed Web of Science ®Google Scholar
• Dvorak HN, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science227(4690), 1059–1061 (1985).
   PubMed Web of Science ®Google Scholar
• Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol.167(5), 2887–2894 (2001).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Ruffini PA, Leifer CA et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science298(5595), 1025–1029 (2002).
   PubMed Web of Science ®Google Scholar
• Yang D, Chertov O, Bykovskaia SN et al. β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science286(5439), 525–528 (1999).
   PubMed Web of Science ®Google Scholar
• Biragyn A, Surenhu M, Yang D et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol.167(11), 6644–6653 (2001).
   PubMed Web of Science ®Google Scholar
• Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem.279(13), 12542–12550 (2004).
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science303(5663), 1526–1529 (2004).
   PubMed Web of Science ®Google Scholar
• Panet A. Regulation of the antiviral and anticellular activities of interferon by exogenous double-stranded RNA. Mol. Cell Biochem.52(2), 153–160 (1983).
   PubMed Web of Science ®Google Scholar
• Lau CM, Broughton C, Tabor AS et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med.202(9), 1171–1177 (2005).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374(6522), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Richardson B. Impact of aging on DNA methylation. Ageing Res. Rev.2(3), 245–261 (2003).
   Google Scholar
• Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum.33(11), 1665–1673 (1990).
   PubMed Web of Science ®Google Scholar
• Sun S, Beard C, Jaenisch R, Jones P, Sprent J. Mitogenicity of DNA from different organisms for murine B cells. J. Immunol.159(7), 3119–3125 (1997).
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell118(2), 229–241 (2004).
   PubMed Web of Science ®Google Scholar
• Jiang D, Liang J, Fan J et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med.11(11), 1173–1179 (2005).
   PubMed Web of Science ®Google Scholar
• van der Heijden IM, Wilbrink B, Tchetverikov I et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum.43(3), 593–598 (2000).
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Arayssi T, Crane M et al. Chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. Arthritis Rheum.42(6), 1281–1284 (1999).
   PubMed Web of Science ®Google Scholar
• Gerard HC, Wang Z, Wang GF et al. Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis. Arthritis Rheum.44(7), 1689–1697 (2001).
   PubMedGoogle Scholar
• Kempsell KE, Cox CJ, Hurle M et al. Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue. Infect. Immun.68(10), 6012–6026 (2000).
   PubMed Web of Science ®Google Scholar
• Chen T, Rimpilainen M, Luukkainen R et al. Bacterial components in the synovial tissue of patients with advanced rheumatoid arthritis or osteoarthritis: analysis with gas chromatography-mass spectrometry and pan-bacterial polymerase chain reaction. Arthritis Rheum.49(3), 328–334 (2003).
   PubMedGoogle Scholar
• Schett G, Redlich K, Xu Q et al. Enhanced expression of heat shock protein 70 (HSP70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of HSP70 expression and HSF1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. J. Clin. Invest.102(2), 302–311 (1998).
   PubMed Web of Science ®Google Scholar
• Scott DL, Delamere JP, Walton KW. The distribution of fibronectin in the pannus in rheumatoid arthritis. Br. J. Exp. Pathol.62(4), 362–368 (1981).
   PubMed Web of Science ®Google Scholar
• Yu D, Rumore PM, Liu Q, Steinman CR. Soluble oligonucleosomal complexes in synovial fluid from inflamed joints. Arthritis Rheum.40(4), 648–654 (1997).
   PubMed Web of Science ®Google Scholar
• Taniguchi N, Kawahara K, Yone K et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum.48(4), 971–981 (2003).
   PubMed Web of Science ®Google Scholar
• Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J. Exp. Med.146(6), 1585–1602 (1977).
   PubMed Web of Science ®Google Scholar
• Joosten LA, Koenders MI, Smeets RL et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J. Immunol.171(11), 6145–6153 (2003).
   PubMed Web of Science ®Google Scholar
• Pierer M, Rethage J, Seibl R et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J. Immunol.172(2), 1256–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Liu ZQ, Deng GM, Foster S, Tarkowski A. Staphylococcal peptidoglycans induce arthritis. Arthritis Res.3(6), 375–380 (2001).
   PubMedGoogle Scholar
• Choe JY, Crain B, Wu SR, Corr M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J. Exp. Med.197(4), 537–542 (2003).
   PubMed Web of Science ®Google Scholar
• Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum.52(9), 2656–2665 (2005).
   PubMed Web of Science ®Google Scholar
• Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum.52(8), 2313–2322 (2005).
   PubMed Web of Science ®Google Scholar
• Kyburz D, Rethage J, Seibl R et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by Toll-like receptor signaling. Arthritis Rheum.48(3), 642–650 (2003).
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science285(5425), 248–251 (1999).
   PubMed Web of Science ®Google Scholar
• Kokkola R, Sundberg E, Ulfgren AK et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum.46(10), 2598–2603 (2002).
   PubMed Web of Science ®Google Scholar
• Kilding R, Akil M, Till S et al. A biologically important single nucleotide polymorphism within the Toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin. Exp. Rheumatol.21(3), 340–342 (2003).
   PubMed Web of Science ®Google Scholar
• Lamb RM, Zeggini E, Thomson W, Donn R. Toll-like receptor 4 (TLR4) gene polymorphisms and susceptibility to juvenile idiopathic arthritis. Ann. Rheum. Dis.64(5), 767–769 (2004).
   PubMed Web of Science ®Google Scholar
• Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin J. Polymorphisms of Toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens63(1), 54–57 (2004).
   PubMed Web of Science ®Google Scholar
• Radstake TR, Franke B, Hanssen S et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum.50(3), 999–1001 (2004).
   PubMed Web of Science ®Google Scholar
• Hong Z, Jiang Z, Liangxi W et al. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int. Immunopharmacol.4(2), 223–234 (2004).
   Google Scholar
• Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford)45(6), 703–710 (2006).
   PubMed Web of Science ®Google Scholar
• Ogawa S, Lozach J, Benner C et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell122(5), 707–721 (2005).
   PubMed Web of Science ®Google Scholar
• Liew FY, Xu D, Brint EK, O’Neill LA. Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol.5(6), 446–458 (2005).
   PubMed Web of Science ®Google Scholar
• Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat. Immunol.6(12), 1198–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Kopp E, Medzhitov R, Carothers J et al. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev.13(16), 2059–2071 (1999).
   Google Scholar
• Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med.3(11), 1285–1289 (1997).
   PubMed Web of Science ®Google Scholar
• de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W. Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol.19(5), 389–394 (2000).
   PubMed Web of Science ®Google Scholar
• Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-α. J. Biol. Chem.275(5), 3687–3692 (2000).
   PubMed Web of Science ®Google Scholar
• Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High DNA-binding activity of transcription factor NF-κB in synovial membranes of patients with rheumatoid arthritis. Biochem. Mol. Biol. Int.37(5), 827–832 (1995).
   PubMedGoogle Scholar
• Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum.38(12), 1762–1770 (1995).
   PubMed Web of Science ®Google Scholar
• Marok R, Winyard PG, Coumbe A et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum.39(4), 583–591 (1996).
   PubMed Web of Science ®Google Scholar
• Foxwell B, Browne K, Bondeson J et al. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proc. Natl Acad. Sci. USA95(14), 8211–8215 (1998).
   PubMed Web of Science ®Google Scholar
• Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell BM. NF-κB-inducing kinase is dispensable for activation of NF-κB in inflammatory settings but essential for lymphotoxin β receptor activation of NF-κB in primary human fibroblasts. J. Immunol.167(10), 5895–5903 (2001).
   PubMed Web of Science ®Google Scholar
• Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl Acad. Sci. USA96(10), 5668–5673 (1999).
   PubMed Web of Science ®Google Scholar
• Miagkov AV, Kovalenko DV, Brown CE et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl Acad. Sci. USA95(23), 13859–13864 (1998).
   PubMed Web of Science ®Google Scholar
• Palombella VJ, Conner EM, Fuseler JW et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl Acad. Sci. USA95(26), 15671–15676 (1998).
   PubMed Web of Science ®Google Scholar
• Tsao PW, Suzuki T, Totsuka R et al. The effect of dexamethasone on the expression of activated NF-κB in adjuvant arthritis. Clin. Immunol. Immunopathol.83(2), 173–178 (1997).
   PubMedGoogle Scholar
• Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nature Rev. Drug Discov.3(1), 17–26 (2004).
   Google Scholar
• Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J. Pharmacol. Exp. Ther.291(1), 124–130 (1999).
   PubMed Web of Science ®Google Scholar
• Schett G, Tohidast-Akrad M, Smolen JS et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum.43(11), 2501–2512 (2000).
   PubMed Web of Science ®Google Scholar
• Dean JL, Brook M, Clark AR, Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem.274(1), 264–269 (1999).
   PubMed Web of Science ®Google Scholar
• Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett.439(1–2), 75–80 (1998).
   PubMed Web of Science ®Google Scholar
• Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-α) mRNA induction. Evidence for selective destabilization of TNF-α transcripts. J. Biol. Chem.276(9), 6666–6674. (2001).
   PubMed Web of Science ®Google Scholar
• Campbell J, Ciesielski CJ, Hunt AE et al. A novel mechanism for TNF-α regulation by p38 MAPK: involvement of NF-κB with implications for therapy in rheumatoid arthritis. J. Immunol.173(11), 6928–6937 (2004).
   PubMed Web of Science ®Google Scholar
• Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther.279(3), 1453–1461 (1996).
   PubMed Web of Science ®Google Scholar
• Jackson JR, Bolognese B, Hillegass L et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther.284(2), 687–692 (1998).
   PubMed Web of Science ®Google Scholar
• Badger AM, Griswold DE, Kapadia R et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum.43(1), 175–183 (2000).
   PubMed Web of Science ®Google Scholar
• Wadsworth SA, Cavender DE, Beers SA et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther.291(2), 680–687 (1999).
   PubMed Web of Science ®Google Scholar
• McLay LM, Halley F, Souness JE et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg. Med. Chem.9(2), 537–554 (2001).
   PubMed Web of Science ®Google Scholar
• Medvedev AE, Lentschat A, Kuhns DB et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med.198(4), 521–531 (2003).
   PubMed Web of Science ®Google Scholar
• Picard C, Puel A, Bonnet M et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science299(5615), 2076–2079 (2003).
   PubMed Web of Science ®Google Scholar
• Kuhns DB, Long Priel DA, Gallin JI. Endotoxin and IL-1 hyporesponsiveness in a patient with recurrent bacterial infections. J. Immunol.158(8), 3959–3964 (1997).
   PubMed Web of Science ®Google Scholar
• Hain R, Reif HJ, Krause E et al. Disease resistance results from foreign phytoalexin expression in a novel plant. Nature361(6408), 153–156 (1993).
   PubMed Web of Science ®Google Scholar
• Hain R, Bieseler B, Kindl H, Schroder G, Stocker R. Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol. Biol.15(2), 325–335 (1990).
   Google Scholar
• Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann. NY Acad. Sci957, 210–229 (2002).
   Google Scholar
• Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J.17(14), 1975–1985 (2003).
   PubMed Web of Science ®Google Scholar
• Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol.175(5), 3339–3346 (2005).
   PubMed Web of Science ®Google Scholar
• Ahn JY, Choi IS, Shim JY et al. The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting Toll-like receptor-mediated inflammatory signals. Eur. J. Immunol.36(1), 37–45 (2006).
   PubMed Web of Science ®Google Scholar
• Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science221(4616), 1181–1183 (1983).
   PubMed Web of Science ®Google Scholar
• Asakura H, Aoshima K, Suga Y et al. Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models. Thromb. Haemost.85(2), 287–290 (2001).
   PubMed Web of Science ®Google Scholar
• Sadeghi K, Wessner B, Laggner U et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol.36(2), 361–370 (2006).
   PubMed Web of Science ®Google Scholar
• Duramad O, Fearon KL, Chang B et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J. Immunol.174(9), 5193–5200 (2005).
   PubMed Web of Science ®Google Scholar
• Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum.50(5), 1686–1689 (2004).
   PubMed Web of Science ®Google Scholar
• Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med.203(3), 553–561 (2006).
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med.202(8), 1131–1139 (2005).
   PubMed Web of Science ®Google Scholar
• Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin–immunoglobulin G complexes. J. Exp. Med.199(12), 1631–1640 (2004).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature420(6917), 868–874 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem.276(20), 16683–16689 (2001).
   PubMed Web of Science ®Google Scholar
• Lee JY, Zhao L, Youn HS et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J. Biol. Chem.279(17), 16971–16979 (2004).
   PubMed Web of Science ®Google Scholar
• Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem.278(3), 1561–1568 (2003).
   PubMed Web of Science ®Google Scholar
• Walton KA, Hsieh X, Gharavi N et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J. Biol. Chem.278(32), 29661–29666 (2003).
   PubMed Web of Science ®Google Scholar
• Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb.14(1), 141–147 (1994).
   PubMed Web of Science ®Google Scholar
• Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA101(29), 10679–10684 (2004).
   PubMed Web of Science ®Google Scholar
• Wright SD, Burton C, Hernandez M et al. Infectious agents are not necessary for murine atherogenesis. J. Exp. Med.191(8), 1437–1442 (2000).
   PubMed Web of Science ®Google Scholar
• Bjorkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med.10(4), 416–421 (2004).
   PubMed Web of Science ®Google Scholar
• Kirii H, Niwa T, Yamada Y et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol.23(4), 656–660 (2003).
   PubMed Web of Science ®Google Scholar
• Elhage R, Jawien J, Rudling M et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res.59(1), 234–240 (2003).
   PubMed Web of Science ®Google Scholar
• Nishina PM, Wang J, Toyofuku W, Kuypers FA, Ishida BY, Paigen B. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids28(7), 599–605 (1993).
   PubMed Web of Science ®Google Scholar
• Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med.347(3), 185–192 (2002).
   PubMed Web of Science ®Google Scholar
• Ameziane N, Beillat T, Verpillat P et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol.23(12), e61–e64 (2003).
   PubMed Web of Science ®Google Scholar
• Roep BO. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes45(9), 1147–1156 (1996).
   PubMed Web of Science ®Google Scholar
• Lang KS, Recher M, Junt T et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med.11(2), 138–145 (2005).
   PubMed Web of Science ®Google Scholar
• Hron JD, Peng SL. Type I IFN protects against murine lupus. J. Immunol.173(3), 2134–2142 (2004).
   PubMed Web of Science ®Google Scholar
• Jingwu Z, Medaer R, Hashim GA, Chin Y, van den Berg-Loonen E, Raus JC. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol.32(3), 330–338 (1992).
   PubMed Web of Science ®Google Scholar
• Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature346(6280), 183–187 (1990).
   PubMed Web of Science ®Google Scholar
• Martin R, Voskuhl R, Flerlage M, McFarlin DE, McFarland HF. Myelin basic protein-specific T-cell responses in identical twins discordant or concordant for multiple sclerosis. Ann. Neurol.34(4), 524–535 (1993).
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet359(9313), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Casetta I, Granieri E. Prognosis of multiple sclerosis: environmental factors. Neurol. Sci.21(4 Suppl. 2), S839–S842 (2000).
   Google Scholar
• Buljevac D, Flach HZ, Hop WC et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain125(Pt 5), 952–960 (2002).
   PubMed Web of Science ®Google Scholar
• Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest.113(7), 990–997 (2004).
   PubMed Web of Science ®Google Scholar
• Kerfoot SM, Long EM, Hickey MJ et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol.173(11), 7070–7077 (2004).
   PubMed Web of Science ®Google Scholar
• Linthicum DS. Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology162(3), 211–220 (1982).
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature411(6837), 599–603 (2001).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature411(6837), 603–606 (2001).
   PubMed Web of Science ®Google Scholar
• Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J. Biol. Chem.278(8), 5509–5512 (2003).
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem.278(11), 8869–8872 (2003).
   PubMed Web of Science ®Google Scholar
• van Heel DA, Ghosh S, Butler M et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur. J. Immunol.35(8), 2471–2476 (2005).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol.5(8), 800–808 (2004).
   PubMed Web of Science ®Google Scholar
• Netea MG, Hijmans A, van Wissen S et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J. Clin. Invest.34(2), 94–99 (2004).
   PubMed Web of Science ®Google Scholar
• Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn’s disease is associated with a Toll-like receptor-9 polymorphism. Gastroenterology127(1), 365–366 (2004).
   Google Scholar
• Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn’s disease. Am. J. Physiol. Gastrointest. Liver Physiol.290(6), G1157–G1163 (2006).
   PubMed Web of Science ®Google Scholar
• McCarty DJ. Crystals and arthritis. Dis. Mon.40(6), 255–299 (1994).
   Google Scholar
• Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum.50(8), 2400–2414 (2004).
   PubMed Web of Science ®Google Scholar
• Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J. Immunol.174(8), 5016–5023 (2005).
   PubMed Web of Science ®Google Scholar
• Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum.52(9), 2936–2946 (2005).
   PubMed Web of Science ®Google Scholar
• Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature440(7081), 237–241 (2006).
   PubMed Web of Science ®Google Scholar
• Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat. Rev. Immunol.6(3), 183–195 (2006).
   PubMed Web of Science ®Google Scholar
• Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol.14(21), 1929–1934 (2004).
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell10(2), 417–426 (2002).
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Newton K, Monack DM et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature430(6996), 213–218 (2004).
   PubMed Web of Science ®Google Scholar